Fusion Antibodies PLC (LON:FAB) CEO Paul Kerr speaks to Proactive London's Andrew Scott following their oversubscribed £3mln fundraise.
He says they now have the resources to carry out additional proof-of-concept work on their Mammalian Antibody Library Discovery Platform, which has been expanded to include COVID-19, as well as for their existing oncology targets.